Flagellin concentrations in expectorations from cystic fibrosis patients

BMC Pulmonary Medicine

Michel Chignard⁶  Dominique Hubert¹  Reuben Ramphal²  Annick Clement⁵  Harriet Corvol⁵  Philippe Morand³  Thierry Bienvenu⁴  Guiti Thévenot¹  Viviane Balloy⁶ 

[1]Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, UPRES EA 2511, Paris, France

[2]Université François Rabelais, UMR 1100, Tours, France

[3]Hôpital Cochin, AP-HP, Service de Bactériologie, Paris, France

[4]Université Paris Descartes, Sorbonne Paris Cité, Inserm U1016, CNRS (UMR 8104), Paris, France

[5]UPMC, Université Paris 6, Inserm, UMR-S U938, Paris, France

[6]Défense innée et Inflammation, Inserm U874, Institut Pasteur, 25, rue du Dr Roux, Paris 75015, France

关键词: Respiratory function;    Infection;    Chronic inflammation;    Sputum;   

Others  :  862786
DOI  :  10.1186/1471-2466-14-100

 received in 2013-12-30, accepted in 2014-05-13,  发布年份 2014

【 摘 要 】

Background

The aim was to measure flagellin concentrations in the expectorations of CF patients and to examine whether there are correlations with the level of respiratory insufficiency and inflammation.

Methods

Sputum samples from 31 adult patients chronically colonized with P. aeruginosa were collected and analysed for their content of flagellin and IL-8. Clinical data were extracted from patient files.

Results

Regardless of whether patients are colonized with mucoid strains or not, they carry clones of P. aeruginosa that express flagellin. While flagellin was present in airways of all of our CF patients, it is difficult to ascertain its contribution to inflammation (IL-8) and lung function deterioration.

Conclusions

This is the first demonstration that flagellin is present in the sputum of patients. Thus, attempts to down regulate inflammation by the use of TLR5 (flagellin receptor) antagonists remain a possibility. However, this result needs to be extended to a larger number of patients to validate it for future research on this subject.

【 授权许可】

   
2014 Balloy et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Callaghan M, McClean S: Bacterial host interactions in cystic fibrosis. Curr Opin Microbiol 2012, 15:71-77.
• [2]Cohen TS, Prince A: Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 2012, 18:509-519.
• [3]Goss CH, Burns JL: Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007, 62:360-367.
• [4]Stenbit AE, Flume PA: Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011, 17:442-447.
• [5]Chotirmall SH, Smith SG, Gunaratnam C, Cosgrove S, Dimitrov BD, O’Neill SJ, Harvey BJ, Greene CM, McElvaney NG: Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012, 366:1978-1986.
• [6]Waters V, Ratjen F: Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008, 3:CD006961.
• [7]Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, Tümmler B, Vavrova V, De Boeck K: Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros 2011, 10(2):S79-S81.
• [8]Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, Galán JE, Flavell RA, Alexopoulou L: Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci U S A 2006, 103:12487-12492.
• [9]Skerrett SJ, Wilson CB, Liggitt HD, Hajjar AM: Redundant Toll-like receptor signaling in the pulmonary host response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2007, 292:L312-L322.
• [10]Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, Chignard M: Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol 2008, 181:586-592.
• [11]Adamo R, Sokol S, Soong G, Gomez MI, Prince A: Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am J Respir Cell Mol Biol 2004, 30:627-634.
• [12]Oshikawa K, Sugiyama AL: Gene expression of Toll-like receptors and associated molecules induced by inflammatory stimuli in the primary alveolar macrophage. Biochem Biophys Res Commun 2003, 305:649-655.
• [13]Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard M, Si-Tahar M: Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 2004, 279:2712-2718.
• [14]Ramos HC, Rumbo M, Sirard JC: Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 2004, 12:509-517.
• [15]Hybiske K, Ichikawa JK, Huang V, Lory SJ, Machen TE: Cystic fibrosis airway epithelial cell polarity and bacterial flagellin determine host response to Pseudomonas aeruginosa. Cell Microbiol 2004, 6:49-63.
• [16]Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, Wilson JM: Human airway epithelial cells sense Pseudomonas aeruginosa infection via recognition of flagellin by Toll-like receptor 5. Infect Immun 2005, 73:7151-7160.
• [17]Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI: Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002, 3:354-359.
• [18]Luzar MA, Thomassen MJ, Montie TC: Flagella and motility alterations in Pseudomonas aeruginosa strains from patients with cystic fibrosis: relationship to patient clinical condition. Infect Immun 1985, 50:577-582.
• [19]Wolfgang MC, Jyot J, Goodman AL, Ramphal R, Lory S: Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. Proc Natl Acad Sci U S A 2004, 101:6664-6668.
• [20]Sonawane A, Jyot J, During R, Ramphal R: Neutrophil elastase, an innate immunity effector molecule, represses flagellin transcription in Pseudomonas aeruginosa. Infect Immun 2006, 74:6682-6689.
• [21]López-Boado YS, Espinola M, Bahr S, Belaaouaj A: Neutrophil serine proteinases cleave bacterial flagellin, abrogating its host response-inducing activity. J Immunol 2004, 172:509-515.
• [22]Sauer K, Camper AK, Ehrlich GD, Costerton JW, Davies DG: Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002, 184:1140-1154.
• [23]Wagner VE, Iglewski BH: P. aeruginosa Biofilms in CF Infection. Clin Rev Allergy Immunol 2008, 35:124-134.
• [24]Whiteley M, Bangera MG, Bumgarner RE, Parsek MR, Teitzel GM, Lory S, Greenberg EP: Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001, 413:860-864.
• [25]Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-Jørgensen A, Molin S, Tolker-Nielsen T: Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol 2003, 48:1511-1524.
• [26]Verma A, Arora SK, Kuravi SK, Ramphal R: Roles of specific amino acids in the N terminus of Pseudomonas aeruginosa flagellin and of flagellin glycosylation in the innate immune response. Infect Immun 2005, 73:8237-8246.
• [27]Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
• [28]Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME: Effect of aerosolized recombinant human DNase on exacerbations of pulmonary symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642.
• [29]Arora SK, Dasgupta N, Lory S, Ramphal R: Identification of two distinct types of flagellar cap proteins, FliD, in Pseudomonas aeruginosa. Infect Immun 2000, 68:1474-1479.
• [30]McIsaac SM, Stadnyk AW, Lin TJ: Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis. J Leukoc Biol 2012, 92:977-985.
• [31]Balloy V, Verma A, Kuravi S, Si-Tahar M, Chignard M, Ramphal R: The role of flagellin versus motility in acute lung disease caused by Pseudomonas aeruginosa. J Infect Dis 2007, 196:289-296.
• [32]Blohmke CJ, Park J, Hirschfeld AF, Victor RE, Schneiderman J, Stefanowicz D, Chilvers MA, Durie PR, Corey M, Zielenski J, Dorfman R, Sandford AJ, Daley D, Turvey SE: TLR5 as an anti-inflammatory target and modifier gene in cystic fibrosis. J Immunol 2010, 185:7731-7738.
• [33]Rieber N, Brand A, Hector A, Graepler-Mainka U, Ost M, Schäfer I, Wecker I, Neri D, Wirth A, Mays L, Zundel S, Fuchs J, Handgretinger R, Stern M, Hogardt M, Döring G, Riethmüller J, Kormann M, Hartl D: Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 2013, 190:1276-1284.
• [34]Workentine ML, Sibley CD, Glezerson B, Purighalla S, Norgaard-Gron JC, Parkins MD, Rabin HR, Surette MG: Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS One 2013, 8:e60225.